Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry

被引:0
|
作者
Munoz-Martinez, C. [1 ]
Segura-Puertas, M. [1 ]
Gomez-Moreno, G. [1 ]
机构
[1] Univ Granada, Sch Dent, Dept Medically Compromised Patients Dent, Granada, Spain
关键词
DMARDs; Drug interactions; Dentistry Non-steroidal anti-inflammatories (NAIDS); Antibiotics; Antifungals; Acetaminophen; PHARMACOLOGICAL INTERACTIONS; RHEUMATOID-ARTHRITIS; METHOTREXATE; ANALGESICS; MANAGEMENT; DIAGNOSIS;
D O I
10.26355/eurrev_202104_25536
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Rheumatoid arthritis is a chronic autoimmune disease. Treatment aims to reduce and improve its signs and symptoms. Hence, Disease-Modifying Antirheumatic Drugs (DMARDs) are the treatment of choice. The objective of this study was to identify potential interactions between DMARDs and the drugs most frequently prescribed in dentistry in order to avoid adverse reactions. MATERIALS AND METHODS: This literature review sets out to define possible adverse reactions provoked by pharmacological interactions between DMARDs and the drugs commonly prescribed in dentistry. A search was conducted in PubMed by searching the names of drugs used in dentistry, "drug interactions," "rheumatoid arthritis," and "dentistry", "hydroxychloroquine". 'leflunomide", "methotrexate", "sulfasalazine . adalimumab", "anakinra", "etanercept", "abatacepC, "infliximab" and "rituximab". RESULTS: It was found that most DMARDs show potential interactions with many drugs used in dentistry, including various antibiotics, analgesics, anesthetics, antifungals, and corticosteroids. CONCLUSIONS: It is clinically important for oral health clinicians to be aware of possible drug interactions between DMARDs and the drugs commonly prescribed in dentistry to prevent potential adverse reactions and avoid endangering the patient.
引用
收藏
页码:2834 / 2842
页数:9
相关论文
共 50 条
  • [31] Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
    G Jansen
    J van der Heijden
    RJ Scheper
    BAC Dijkmans
    [J]. Arthritis Research & Therapy, 4 (Suppl 1)
  • [32] PARTICULARITIES OF TREATMENT WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Schiotis, Ruxandra Elena
    Gosa, Dana
    Bocsan, Corina
    Suciu, Soimita
    Buzoianu, Anca Dana
    [J]. FARMACIA, 2017, 65 (03) : 479 - 484
  • [33] ROMAZARIT - A POTENTIAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG
    SELF, CR
    BARBER, WE
    MACHIN, PJ
    OSBOND, JM
    SMITHEN, CE
    TONG, BP
    WICKENS, JC
    BLOXHAM, DP
    BRADSHAW, D
    CASHIN, CH
    DODGE, BB
    LEWIS, EJ
    WESTMACOTT, D
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) : 772 - 777
  • [34] Managing Disease-Modifying Antirheumatic Drugs (DMARDs) for Patients Undergoing Elective Spine Surgery: A Pilot Survey
    Mamaril-Davis, James C.
    Aguilar-Salinas, Pedro
    Aguirre, Salvador Fabian Gutierrez
    Avila, Mauricio J.
    Villatoro-Villar, Michel
    Riordan, Katherine
    Dumont, Travis M.
    [J]. SPINE SURGERY AND RELATED RESEARCH, 2024, 8 (01): : 35 - 42
  • [35] POSTOPERATIVE COMPLICATIONS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING RITUXIMAB AND CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)
    Pogozheva, E.
    Amirdzhanova, V.
    Makarov, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 882 - 882
  • [36] IGURATIMOD: A NEW DISEASE-MODIFYING ANTIRHEUMATIC DRUG
    Mucke, H. A. M.
    [J]. DRUGS OF TODAY, 2012, 48 (09) : 577 - 586
  • [37] Putting new disease-modifying antirheumatic drugs into perspective
    Saseen, Joseph J.
    [J]. PHARMACOTHERAPY, 2007, 27 (12): : 1609 - 1610
  • [38] Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis
    Wendling, Daniel
    Prati, Clement
    [J]. IMMUNOTHERAPY, 2017, 9 (03) : 221 - 223
  • [39] Perinatal Use and Discontinuation of Disease-Modifying Antirheumatic Drugs
    Rebic, Nevena
    De Vera, Mary A.
    Gupta, Amit
    Amiri, Neda
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (05) : 188 - 192
  • [40] A clinical and economic review of disease-modifying antirheumatic drugs
    Gabriel, SE
    Coyle, D
    Moreland, LW
    [J]. PHARMACOECONOMICS, 2001, 19 (07) : 715 - 728